Perlmutter Cancer Center

If you or your child has been diagnosed with low-grade gliomas, you or your child may qualify to participate in a study evaluating the safety and effectiveness of the investigational drug, MEK162, a dual specific kinase inhibitor, which blocks a critical regulator in a key pathway that helps control cells' ability to grow and survive.  The main goal of this phase I-II study is to find out what effects, good and/or bad, MEK162 has on people with low-grade gliomas.  In addition, we would like to explore the pharmacodynamic effect of the investigational drug, MEK162 on biomarkers (proteins) of a specific signaling pathway.  This study will be conducted in two phases:  Phase I will consist of defining the toxicity profile of the investigational drug.  Phase II will help determine how the investigational drug reacts to your cancer.